Connect with us

BenzingaEditorial

The IPO Week Ahead

Published

on

11 IPOs have been scheduled this week, aiming to raise more than $2.7 billion, led by dating app Bumble’s billion-dollar offering.

Bumble

Bumble (NASDAQ: BMBL) operates the Bumble and Badoo apps, the world’s second and fourth highest grossing dating apps. It initially planned to raise $1.0 billion at a $5.8 billion market cap. On Monday, it raised the size of its IPO offering to 45 million shares, now expecting to raise $1.8 billion and targeting a valuation of $7 billion. Operating in a competitive market with low barriers to entry, Bumble was profitable on an EBITDA basis in the first three quarters of 2020, with growth accelerating in the most recent quarter. The filing reveals its average monthly userbase has 42 million, out of which 2.4 million are paying users.

Signify Health

A value-based billing platform for in-home and bundled health services, Signify Health (NASDAQ: SGFY), plans to raise 423 million at a $4.1 billion market cap. The Norway-based company has demonstrated growth and was profitable on an EBIT basis during the first nine months of 2020.

loanDepot

After delaying its IPO last week, the nonbank lender loanDepot (NASDAQ: LDI) now plans to raise $300 million at a $6.2 billion market cap. The company offers loan origination and servicing, while focusing on mortgage and unsecured personal loans. Although it is fast growing and profitable, it operates in a highly cyclical industry and if we are to judge by recent mortgage lenders that went public, there probably won’t be much of a reception.

Cloopen Group Holding

China’s largest multi-capability cloud-based communications solution provider by 2019 revenue, Cloopen Group Holding (NASDAQ: RAAS) plans to raise $280 million at a $2.1 billion market cap. Unprofitable with decelerating growth during the first nine months of 2020, Cloopen Group had an active customer base of over 12,000 enterprises as of the end of September 2020.

Viant Technology

Advertising software maker Viant Technology (NASDAQ: DSP) initially planned to raise $150 million at a $1.3 billion market cap. The Irvine, CA-based company raised the deal size by 30% and it now plans to raise $196 million. The company’s software brings programmatic advertising to life by enabing the electronification of the advertising buying process. While the company’s active customers declined during the first three quarters of 2020, average revenue ex-TAC per active customer rose 23% YoY.

Apria

A provider of integrated home healthcare equipment and services, Apria (NASDAQ: APR) plans to raise $150 million at a $756 million market cap. The company is profitable but it is growing slowly, having served almost 2 million patients, with 2.4 million deliveries, and over 744,000 clinician interactions with patients in 2019.

Adagene

Chinese cancer biotech Adagene (NASDAQ: ADAG) plans to raise $132 million at an $831 million market cap. Its most advanced candidate ADG106 is undergoing Phase 1 trials both in the US and China. The drug that is designed to target a unique antibody that is different from any anti-CD137 antibodies currently in development.

Bioventus

After four years, orthobiologic therapy developer Bioventus (NASDAQ: BVS) is hoping that second time’s the charm as it plans to raise $125 million at a $922 million market cap. The company’s competitive advantage lies in developing and commercializing clinically differentiated, cost efficient, and minimally invasive treatments that aim to boost the body’s natural healing capability. It is profitable despite revenue falling due to COVID-related declines in volume during the first three quarters of 2020.

REIT AFC Gamma

Cannabis finance REIT AFC Gamma (NASDAQ: AFCG) plans to raise $100 million at a $214 million market cap. A West Palm Beach, Florida-based company was founded in July 2020 and it offers loans to established cannabis companies in states where marijuana is legal for medical or recreational use.

Longeveron

Cell therapy biotech Longeveron (NASDAQ: LGVN) plans to raise $25 million at a $194 million market cap. Longeveron is developing cellular therapies for specific aging and life-threatening conditions. It is currently sponsoring Phase 1 and 2 trials in five indications of its lead product.

Biophytis

French-listed biotech Biophytis (NASDAQ: BPTS) plans to raise $20 million at a $195 million market cap. Its lead candidate is an orally administered small molecule in development for the treatment of neuromuscular diseases and is currently in a Phase 2 trial for sarcopenia, with top-line results expected in the 2Q21, along with an ongoing Phase 2/3 study for SARS-CoV-2 pneumonia.

The IPO market is still hot

By the looks of it, the IPO market is not losing momentum and we are in for another diverse IPO week, including dating, cannabis, communication with biotech and healthcare leading the way.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BenzingaEditorial

Johnson & Johnson’s Vaccine Is on Hold But lts Businesses Emerged Healthier From the Pandemic

Published

on

On Tuesday, Johnson and Johnson (NYSE: JNJ) reported $100 million in first-quarter sales of its single shot Covid-19 vaccine that’s on hold in the U.S. due to a rare and potentially life-threatening blood clotting disorder which has been also related to AstraZeneca (NASDAQ: AZN) vaccine which still hasn’t been approved for emergency use in the U.S. But on the financial side, the company exceeded Wall Street estimated both in terms of revenue and earnings.

First quarter figures

Adjusted EPS amounted to $2.59 per share, exceeding the expected $2.34. Revenue amounted to $22.32 billion, also topping the expected $21.98 billion.

The pharmaceutical business behind the vaccine generated $12.19 billion in revenue. Sales sales of the company’s multiple myeloma drug and a treatment for Crohn’s disease also did their part in fueling the 9.6% YoY increase.

The consumer unit which makes products such as Neutrogena face wash and Listerine mouth wash, generated $3.5 billion in revenue. The drop of 2.3% from a year earlier was due to an “unfavorable comparison” to last year when people were stockpiling on over-the counter- products due to the pandemic-induced lockdowns.

The medical device unit was hit hard last year as hospitals were forced to postpone elective surgeries but it now generated $6.57 billion, a 7.9% increase, as the pandemic recovery is underway.

The FDA halts JNJ’s vaccine production

On Wednesday, The US Food and Drug Administration put the production of Johnson & Johnson’s vaccine on pause at the Emergent BioSolutions facility where millions of potential doses were contaminated.

Already manufactured vaccines will undergo additional testing to ensure their quality hasn’t been compromised before any potential distribution. According to the report, the emergent facility is deeply flawed as written procedures to prevent cross-contamination weren’t followed during production or documented. Components and product containers were not handled or stored in a way to prevent contamination whereas written procedures to assure drug substances are manufactured at the appropriate quality, strength and purity were found inadequate. The report also notes that employees weren’t properly trained and that the facility is of inadequate size or design to allow adequate cleaning and sanitization. Besides unsuitable equipment, the inspection noted peeling paint, unsealed bags of medical waste, residue on walls and damaged floors and rough surface all of which prevent pursuing the intended protocol.

Meanwhile, JNJ is confident about emerging stronger from the pandemic

The CFO, Joseph Wolk told CNBC on Tuesday that the three business segments are “healthier” than they were before COVID-19 shaped our reality last year. The company slightly raised its earnings and revenue guidance for the year as it now expects full-year profit in the range between $9.42 to $9.57 per share with revenue between $90.6 billion and $91.6 billion.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

It Seems Netflix Has Been Dethroned

Published

on

Netflix (NASDAQ: NFLX) shares fell as much as 11% in after-hours trading after the streaming giant reported a large miss in subscriber numbers in its first-quarter earnings report. The facts that revenue still grew on a YoY basis along with a strong beat on earnings were not enough to offset the weak number of subscriber additions, especially as management only expects 1 million new subscribers in the undergoing quarter.

First quarter figures

Revenue amounted to $7.16 billion, slightly topping $7.13 billion expected, resulting in earnings per share of $3.75 that exceed the expected $2.97, as gathered by Refinitiv. Global paid net subscriber additions came at 3.98 million which is significantly below the 6.2 million expected, according to FactSet. This figure seems even more pessimistic compared to a quarterly record of 15.8 million new paying users it gathered during the first three months of 2020.

Still, the company’s revenue grew 24% YoY and was in line with its beginning of quarter forecast. Netflix also delivered a strong beat on earnings compared to Street estimates. Operating income for the quarter came in at $1.96 billion which is more than double $958 million in the year-earlier period. Moreover, as content spending was lower, it resulted in a 27% operating margin which is an all-time high for the first quarter.

Netflix is losing subscribers

Netflix believes that the shortfall subscriber numbers could be blamed on the ongoing pandemic or more precisely on its smaller pipeline of originals as COVID-19 restrictions forced the company to delay some of its big-name shows and films. It doesn’t believe that competition from Walt Disney Company’s (NYSE: DIS) Disney+ and Hulu, AT&T’s (NYSE: T) HBO Max, Apple’s (NASDAQ: AAPL) Apple TV+ , Amazon’s (NASDAQ: AMZN) Prime video and Comcast Corporation’s (NASDAQ: CMCSA) NBCUniversal’s Peacock played a factor in the weak subscriber numbers. But the reality is that Netflix is facing an increasing set of competitors in the streaming space with HBO Max having reached 41 million U.S. subscribers two years ahead of schedule in January this year and Disney+ topping 100 million global subscribers as of early March, ballooning to about half of Netflix’s 208 million worldwide subscribers only within a year-and-a-half of its launch.

The key is the business remains healthy and that it keeps growing

To respond its competitors, Netflix expects to spend more than $17 billion in cash on content this year. Production is up and running in nearly all of its major markets and While ramping up content spending more than 44% compared with $11.8 billion last year, Netflix is also trying to combat password sharing. Historically, it wasn’t concerned about this issue as subscriber growth and stock price were easily offsetting concerns around lost revenue. But, things changed as Netflix has found itself amid intense ‘streaming wars’.

Netflix’s board approved a buyback program to repurchase up to $5 billion in common stock, beginning in 2021 with no fixed expiration date. The program is expected to begin during the quarter.

The winner of the streaming wars is still unknown

While Netflix matures in terms of subscriber growth, its business has also become increasingly efficient from an operating standpoint, despite channeling billions into content creation. After posting its first full-year of positive free cash flow since 2011 last year, it believes it is “very close to being sustainably” free cash flow positive.  As for 2021, it expects free cash flow to be around breakeven while no longer having to raise external financing for its day-to-day operations.  In other words, it’s been more than a year that streaming wars intensified and all players are investing heavily to be on the winning side even after the world successfully combats COVID-19.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Coca Cola Made a Sparkling Recovery

Published

on

Coca-Cola’s (NYSE: KO) business was hit extra hard during the COVID-19 pandemic as people avoided gatherings with events being cancelled across the globe. As its business model is heavily reliant on these point-of-sale drinks, the pandemic translated into sharp volume drops for fiscal 2020 while peers like PepsiCo (NASDAQ: PEP) enjoyed booming demand at supermarkets and warehouse retailers. However, on Monday, the beverage giant showed it rebounded by beating on earnings with demand in March hitting pre-pandemic levels.

Fiscal first-quarter

Net sales rose 5% as they amounted to $9.02 billion, exceeding estimates of $8.6 billion. Organic revenues grew 6%, but unit case volume was flat compared to a year earlier. Demand improved every month of the quarter, driven by markets like China where uncertainty concerns around the virus eased.

Coca Cola reported a net income of $2.25 billion, or 52 cents per share. This is a drop compared to last year’s $2.78 billion, or 64 cents per share. Excluding items, earnings amounted to 55 cents per share, exceeding the 50 cents per share expected by analysts surveyed by Refinitiv.

Coca Cola has done a great job focusing on what it can control

Through the pandemic, executives slashed costs by finding ways to cut supply chain, marketing, production and packaging expenses, leading to rising profitability even as peer PepsiCo’s margins fell.

At the beginning of the year, management said the first quarter would be the hardest of the year, but that the scale of the recovery that follows would depend on big variables like the pace of vaccine distribution.

Unchanged demand

Quarterly demand was unchanged from a year earlier as North America and Western Europe take longer to recover from the pandemic but global unit case volume in March returned to 2019 levels.

While the central North American business is still under pressure, growth in India, China and Latin America managed to offset those declines. Nutrition, juice, dairy and plant-based beverage segment experienced a 3% volume growth as it was fueled by higher demand in China and India. Hydration, sports, coffee and tea segment was the hardest hit with volumes shrinking 11%. The coffee business declined 21% as Costa cafeswere heavily impacted by the lockdowns. The hydration category that includes Dasani and Smartwater reported volume declines of 12% as consumers across the globe bought less single-use water bottles. Demand for tea products fell 6%, whereas sports drinks saw volume decline slightly by 1%.

Uncertainty still remains

Back in February, management stated that the giant has positioning itself to come out of the crisis targeting faster growth and higher margins compared to its pre-pandemic figures.

The company restated its full-year forecast, with organic revenue growth expected in high single digits and adjusted earnings growth expected in the range between high single digits to low double digits. India and parts of Europe are reintroducing lockdowns due to spikes in new Covid-19 cases, while Latin America and Africa are expecting slower vaccine distribution and embracing for new waves. While vaccinations are rising in many countries such as the U.S., U.K., the flip side is there’s actually a new high in terms of cases as the weekly number of new cases has just hit an all-time peak.

Although April has started well for Coke, the looming risk of new lockdowns threatens to reverse that progress.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Advertisement

TRENDING

Advertisement

Submit an Article

Send us your details and the subject of your article and an IAM editor will be in touch with you shortly

Trending